Haemonetics Corporation (HAE)

Market Cap	4.23B
Revenue (ttm)	1.31B
Net Income (ttm)	117.56M
Shares Out	50.95M
EPS (ttm)	2.29
PE Ratio	36.27
Forward PE	17.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	284,556
Open	83.10
Previous Close	82.73
Day's Range	82.40 - 83.51
52-Week Range	70.74 - 97.97
Beta	0.37
Analysts	Buy
Price Target	109.50 (+31.83%)
Earnings Date	Aug 6, 2024

About HAE

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provi...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,657
• Stock Exchange: NYSE
• Ticker Symbol: HAE

Financial Performance

In 2023, Haemonetics's revenue was $1.31 billion, an increase of 12.01% compared to the previous year's $1.17 billion. Earnings were $117.56 million, an increase of 1.87%.

Analyst Forecast

According to 4 analysts, the average rating for HAE stock is "Buy." The 12-month stock price forecast is $109.5, which is an increase of 31.83% from the latest price.

Price Target

$109.5

(31.83% upside)

Analyst Consensus: Buy